Date:1/26/2009

1,121(a) (a) - (r) See explanatory notes on the following pages. Amgen Inc. Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings (In millions, except per share data) (Unaudited) (a) To exclude the impact of stock option expense recorded in accordance with Statement of Financial Accounting Standards ("SFAS") No. 123R. For the three and twelve months ended December 31, 2008 and 2007, the total pre-tax expense for employee stock options in accordance with SFAS No. 123R was $26 million and $103 million, respectively, and $41 million and $181 million, respectively. "Adjusted" diluted EPS including the impact of stock option expense for the three and twelve months ended December 31, 2008 and 2007 was as follows: Three months ended Year ended December 31, December 31, ------------ ------------ 2008 2007 2008 2007 ---- ---- ---- ---- "Adjusted" diluted EPS, excluding stock option expense $1.06 $1.00 $4.55 $4.29 Impact of stock option expense (net of tax) (0.02) (0.03) (0.07) (0.12) ----- ----- ----- ----- "Adjusted" diluted EPS, including stock option expense $1.04 $0.97 $4.48 $4.17 ===== ===== ===== ===== (b) To exclude the following restructuring (expenses)/recoveries associated with our restructuring plan announced in August 2007, as follows: Separ- Asset
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results